Indeed, several small molecule that inhibit GCN5 (i.e. MB‐3) have been discovered and already taken into consideration for the treatment of different pathologies associated with GCN5 dysregulation like type 2 diabetes, insulin resistance, metabolic disease and syndrome, dyslipidaemia, obesity or overweight, neurodegenerative diseases, heart failure, muscle diseases and improvement of exercise endurance capacity.39, 40. Here, KAT2B is linked to inherited lipid metabolism disorder.